Theriva Biologics, Inc. (TOVX)
NYSEAMERICAN: TOVX · Real-Time Price · USD
0.3540
-0.0060 (-1.67%)
May 8, 2026, 4:00 PM EDT - Market closed
Theriva Biologics Employees
As of December 31, 2025, Theriva Biologics had 16 total employees, including 15 full-time and 1 part-time employees. The number of employees decreased by 6 or -27.27% compared to the previous year.
Employees
16
Change (1Y)
-6
Growth (1Y)
-27.27%
Revenue / Employee
$18,750
Profits / Employee
-$1,435,563
Market Cap
16.25M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 16 | -6 | -27.27% | 15 | 1 |
| Dec 31, 2024 | 22 | 0 | - | 20 | 2 |
| Dec 31, 2023 | 22 | 1 | 4.76% | 22 | 0 |
| Dec 31, 2022 | 21 | 5 | 31.25% | 21 | 0 |
| Dec 31, 2021 | 16 | 6 | 60.00% | 16 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioLineRx | 24 |
| Citius Pharmaceuticals | 23 |
| OSR Holdings | 22 |
| IN8bio | 17 |
| SeaStar Medical Holding | 17 |
| NewcelX | 15 |
| Lipocine | 14 |
| Genenta Science | 9 |
TOVX News
- 4 days ago - Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results - GlobeNewsWire
- 22 days ago - Theriva Biologics to present additional data on Phase 2b VCN-01Clinical Trial - TheFly
- 22 days ago - Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting - GlobeNewsWire
- 5 weeks ago - Theriva Biologics upgraded to Buy at Maxim on clearer VCN-01 path - TheFly
- 5 weeks ago - Theriva Biologics upgraded to Buy from Hold at Maxim - TheFly
- 6 weeks ago - Theriva Biologics announces outcome of Type B End-of-Phase 2 meeting with FDA - TheFly
- 2 months ago - Theriva Biologics price target lowered to $4 from $7 at Alliance Global - TheFly
- 2 months ago - Theriva Biologics reports FY25 EPS ($2.08) vs. ($19.03) last year - TheFly